Langerhans cell histiocytosis in a young patient with Pitt-Hopkins syndrome.
Marina MacchiaioloFilippo Maria PanfiliMichaela Veronika GonfiantiniGerarda MastrogiorgioPaola Sabrina BuonuomoStefania GaspariDaniela LongoMarcella ZollinoAndrea BartuliPublished in: American journal of medical genetics. Part A (2020)
Pitt-Hopkins syndrome (PTHS, MIM #610954) is a rare neurodevelopmental disease characterized by the association of intellectual disability, characteristic facial gestalt and episodes of abnormal and irregular breathing. PTHS is due to heterozygous loss-of-function variants in the TCF4 gene (transcription factor 4, MIM #602272) encoding for a basic helix-loop-helix transcription factor. TCF4 is highly expressed during early development of the nervous system, and it is involved in cellular differentiation and proliferation. Since the first clinical description in 1978, less than 200 PTHS patients have been described. A comprehensive phenotype, especially regarding cancer predisposition, is not yet well defined. We report the case of a 7-year-old boy affected by PTHS with a 4-week history of progressive swelling of the frontal bones diagnosed with Langerhans cell histiocytosis.
Keyphrases
- transcription factor
- intellectual disability
- dna binding
- case report
- end stage renal disease
- single cell
- autism spectrum disorder
- cell therapy
- copy number
- ejection fraction
- newly diagnosed
- chronic kidney disease
- multiple sclerosis
- genome wide identification
- papillary thyroid
- prognostic factors
- early onset
- signaling pathway
- peritoneal dialysis
- genome wide
- clinical trial
- gene expression
- randomized controlled trial
- working memory
- congenital heart disease
- soft tissue
- squamous cell
- lymph node metastasis
- young adults